2017
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
Collaboration T, Trickey A, May M, Vehreschild J, Obel N, Gill M, Crane H, Boesecke C, Patterson S, Grabar S, Cazanave C, Cavassini M, Shepherd L, Monforte A, van Sighem A, Saag M, Lampe F, Hernando V, Montero M, Zangerle R, Justice A, Sterling T, Ingle S, Sterne J. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Lancet HIV 2017, 4: e349-e356. PMID: 28501495, PMCID: PMC5555438, DOI: 10.1016/s2352-3018(17)30066-8.Peer-Reviewed Original ResearchConceptsInitiation of ARTAntiretroviral therapyART initiationCause mortalityHazard ratioLife expectancyCalendar periodCause-specific mortality hazard ratiosYears of ARTFirst yearHIV-1 cohortToxic antiretroviral drugsCombination antiretroviral therapyHIV-positive patientsCD4 cell countManagement of comorbiditiesMortality hazard ratioUK Medical Research CouncilHealth care plannersMedical Research CouncilEDCTP2 programmeCohort studyViral loadAntiretroviral drugsYear survival
2011
Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America
Abraham AG, Lau B, Deeks S, Moore RD, Zhang J, Eron J, Harrigan R, Gill MJ, Kitahata M, Klein M, Napravnik S, Rachlis A, Rodriguez B, Rourke S, Benson C, Bosch R, Collier A, Gebo K, Goedert J, Hogg R, Horberg M, Jacobson L, Justice A, Kirk G, Martin J, McKaig R, Silverberg M, Sterling T, Thorne J, Willig J, Gange SJ, AIDS F. Missing Data on the Estimation of the Prevalence of Accumulated Human Immunodeficiency Virus Drug Resistance in Patients Treated With Antiretroviral Drugs in North America. American Journal Of Epidemiology 2011, 174: 727-735. PMID: 21813792, PMCID: PMC3202147, DOI: 10.1093/aje/kwr141.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusDrug resistanceGenotype testNorth American AIDS Cohort CollaborationHuman immunodeficiency virus drug resistanceGenotypic Resistance Interpretation AlgorithmClinic-based cohortAntiretroviral drug classesAntiretroviral drug resistanceResistance interpretation algorithmsVirus drug resistanceCopies/mLHIV drug resistanceClinical knowledgeDrug resistance mutationsPrevalence of resistanceCohort CollaborationViral loadImmunodeficiency virusAntiretroviral drugsDrug classesClinical carePatientsPrevalenceMultiple imputation method
2009
Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal
Mocroft A, Sterne J, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. Clinical Infectious Diseases 2009, 48: 1138-1151. PMID: 19275498, PMCID: PMC3032444, DOI: 10.1086/597468.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyMortality hazard ratioAntiretroviral therapyHazard ratioCombination antiretroviral therapy eraClinical end point trialsAntiretroviral therapy eraHIV transmission groupEnd point trialHIV RNA loadPneumocystis jiroveci pneumoniaProgressive multifocal leukoencephalopathyMortality of AIDSProportional hazards modelCommon ADEsMedian followTherapy eraJiroveci pneumoniaMultifocal leukoencephalopathyEsophageal candidiasisImmunodeficiency syndromeHodgkin's lymphomaRNA loadAntiretroviral drugsKaposi's sarcoma